FDG positron emission tomographic imaging of thoracic Castleman's disease

被引:18
作者
Reddy, MP
Graham, MM
机构
[1] Univ Iowa Hosp & Clin, Dept Radiol, Div Nucl Med, Iowa City, IA 52242 USA
[2] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA
关键词
Castleman's disease; fluorodeoxyglucose; positron emission tomography; pulmonary nodule;
D O I
10.1097/01.RLU.0000057615.73933.2F
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Fluorodeoxyglucose (FDG) positron emission tomography (PET) has been used to characterize single pulmonary nodules and to stage lung cancer. A cut-off threshold standardized uptake value of 2.5 is reported to provide optimal sensitivity and specificity in distinguishing benign and malignant lesions. The authors describe a patient with a single left hilar lesion on an F-18 FDG-PET scan that was thought to be malignant, but this was proved histopathologically to be Castleman's disease. When PET studies are interpreted, in addition to other benign conditions such as granulomas, infection, and inflammatory processes, clinicians should consider disorders such as Castleman's disease.
引用
收藏
页码:325 / 326
页数:2
相关论文
共 10 条
[1]  
Bowne WB, 1999, CANCER, V85, P706, DOI 10.1002/(SICI)1097-0142(19990201)85:3<706::AID-CNCR21>3.0.CO
[2]  
2-7
[3]   Differentiating benign from malignant lung lesions using ''quantitative'' parameters of FDG PET images [J].
Hubner, KF ;
Buonocore, E ;
Gould, HR ;
Thie, J ;
Smith, GT ;
Stephens, S ;
Dickey, J .
CLINICAL NUCLEAR MEDICINE, 1996, 21 (12) :941-949
[4]  
KANE LW, 1954, NEW ENGL J MED, V250, P26
[5]  
KELLER AR, 1972, CANCER-AM CANCER SOC, V29, P670, DOI 10.1002/1097-0142(197203)29:3<670::AID-CNCR2820290321>3.0.CO
[6]  
2-#
[7]  
KIM JH, 1995, ANN THORAC SURG, V59, P1162
[8]  
Murphy SP, 1997, J NUCL MED, V38, P1211
[9]   FOCAL PULMONARY ABNORMALITIES - EVALUATION WITH F-18 FLUORODEOXYGLUCOSE PET SCANNING [J].
PATZ, EF ;
LOWE, VJ ;
HOFFMAN, JM ;
PAINE, SS ;
BURROWES, P ;
COLEMAN, RE ;
GOODMAN, PC .
RADIOLOGY, 1993, 188 (02) :487-490
[10]  
PETERSON BA, 1993, SEMIN ONCOL, V20, P636